Your browser is no longer supported. Please, upgrade your browser.
Settings
ESRX [NASD]
Express Scripts Holding Company
IndexS&P 500 P/E31.68 EPS (ttm)2.66 Insider Own0.10% Shs Outstand726.90M Perf Week-0.31%
Market Cap61.26B Forward P/E14.01 EPS next Y6.02 Insider Trans-15.01% Shs Float725.22M Perf Month2.94%
Income2.01B PEG2.46 EPS next Q1.10 Inst Own88.70% Short Float2.43% Perf Quarter0.19%
Sales100.89B P/S0.61 EPS this Y14.30% Inst Trans1.49% Short Ratio4.50 Perf Half Y14.40%
Book/sh27.48 P/B3.07 EPS next Y10.73% ROA3.70% Target Price93.45 Perf Year9.24%
Cash/sh2.52 P/C33.43 EPS next 5Y12.90% ROE9.70% 52W Range64.64 - 88.83 Perf YTD-0.46%
Dividend- P/FCF14.90 EPS past 5Y11.20% ROI7.60% 52W High-5.12% Beta1.17
Dividend %- Quick Ratio0.50 Sales past 5Y32.50% Gross Margin7.90% 52W Low30.38% ATR1.44
Employees29500 Current Ratio0.60 Sales Q/Q2.10% Oper. Margin3.60% RSI (14)48.92 Volatility1.24% 1.60%
OptionableYes Debt/Eq0.68 EPS Q/Q21.50% Profit Margin2.00% Rel Volume0.89 Prev Close84.83
ShortableYes LT Debt/Eq0.55 EarningsFeb 23 AMC Payout0.00% Avg Volume3.92M Price84.28
Recom2.20 SMA20-0.22% SMA500.13% SMA20010.93% Volume3,457,700 Change-0.65%
Feb-24-15Reiterated Mizuho Buy $94 → $98
Feb-24-15Reiterated Maxim Group Buy $90 → $109
Jan-28-15Downgrade FBR Capital Outperform → Mkt Perform
Jan-08-15Reiterated Mizuho Buy $82 → $94
Dec-16-14Reiterated Oppenheimer Outperform $82 → $88
Dec-15-14Reiterated UBS Buy $82 → $96
Dec-04-14Reiterated Deutsche Bank Hold $76 → $88
Dec-03-14Reiterated Barclays Overweight $83 → $94
Oct-30-14Reiterated RBC Capital Mkts Outperform $73 → $82
Jul-30-14Reiterated FBR Capital Outperform $79 → $74
Jul-28-14Reiterated UBS Buy $90 → $82
May-01-14Reiterated Maxim Group Buy $92 → $90
Apr-30-14Reiterated Mizuho Buy $86 → $82
Mar-06-14Reiterated Deutsche Bank Hold $75 → $79
Mar-05-14Reiterated RBC Capital Mkts Outperform $72 → $84
Mar-05-14Initiated Barclays Overweight $85
Feb-21-14Reiterated FBR Capital Outperform $75 → $83
Feb-19-14Reiterated Maxim Group Buy $80 → $92
Feb-18-14Downgrade Monness Crespi & Hardt Buy → Neutral
Jan-17-14Reiterated Mizuho Buy $74 → $86
Mar-04-15 01:44PM  Three trades to go before the closing bell at CNBC
12:59PM  FMHR Final Trade: ESRX, EXXI & JNJ CNBC
10:10AM  UBS Makes Big Changes to Equity Focus List For March at 24/7 Wall St.
Mar-02-15 02:19PM  Rolfe: We'll own Berkshire many years to come CNBC
10:00AM  An Obamacare ETF Keeps Rising ETF Trends
Feb-28-15 11:04AM  5 Stocks Warren Buffett Is Selling: Exxon, ConocoPhillips and More at TheStreet
Feb-27-15 11:48AM  Horizon Pharma Soars On Q4 Beat, Guidance Raise at Investor's Business Daily
08:30AM  Trade Healthcare Providers with this ETF at Investopedia
Feb-26-15 03:55PM  Health Care Stocks Flexing Their Muscle at Forbes
02:19PM  The Drug Pipeline Flows Again at Bloomberg
11:59AM  Catamaran EPS Tops, But Stock Falls On Weak Guidance at Investor's Business Daily
11:08AM  6 reasons biotech stocks may soon tank at MarketWatch
Feb-25-15 02:19PM  Express Scripts Holding (ESRX) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
12:09PM  Story Stocks from Briefing.com Briefing.com
10:38AM  Gilead & AbbVie: It Doesn't Matter Which Drug is Better, Just Who Will Pay at Barrons.com
Feb-24-15 05:30PM  Stocks End at New Record Highs; Yellen, Grecce Eyed Morningstar
12:00PM  Stocks Rise; Yellen Testimony, Greece in Focus Morningstar
10:21AM  Waiting for Yellen Q&A, but QE helping elsewhere at CNBC
10:10AM  Company News for February 24, 2015 - Corporate Summary Zacks
09:30AM  Express Scripts (ESRX) Beats on Q4 Earnings & Revenues - Analyst Blog Zacks
09:10AM  What We're Trading Yahoo Finance Contributors
08:52AM  Morning Movers: JPMorgan Shares Higher on Investor Day; Home Depot Jumps on Earnings at Barrons.com
08:30AM  Express Scripts Holding Co Earnings Call scheduled for 8:30 am ET today CCBN
08:15AM  Early movers: HD, CMCSA, TOL, ODP, JPM & more at CNBC
Feb-23-15 07:00PM  Cramer: Watch out - regulators are gunning for these stoc... CNBC
05:46PM  First Solar, SunPower shares surge on joint IPO at MarketWatch
05:21PM  After-hours buzz: Express Scripts, SunPower & more at CNBC
05:09PM  Express Scripts rises after-hours following 4Q report AP
05:03PM  Nasdaq Stretches Win Streak To 9 Days at Investor's Business Daily
04:45PM  Is Express Scripts 2015 Guidance Good Enough For All-Time Highs? at 24/7 Wall St.
04:37PM  Express Scripts tops Street 4Q forecasts AP
04:26PM  Express Scripts shares seesaw on earnings beat, outlook at MarketWatch
04:09PM  EXPRESS SCRIPTS HOLDING CO. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or EDGAR Online
04:07PM  Express Scripts beats Street 4Q forecasts AP
04:01PM  Express Scripts Announces 4th Quarter Results; Provides Initial 2015 Earnings Guidance PR Newswire
04:00PM  US stocks close near highs ahead of Yellen testimony at CNBC
08:09AM  Wall Street uneasy after Greece deal; Yellen eyed at CNBC
07:07AM  Q4 2014 Express Scripts Holding Co Earnings Release - After Market Close CCBN
Feb-20-15 06:15PM  Cramer's game plan: Expect major news on this at CNBC
03:47PM  US still the place to be: Delphi's Scott Black at CNBC
12:00PM  Will Express Scripts (ESRX) Beat Q4 Earnings Estimates? - Analyst Blog Zacks
Feb-19-15 07:38AM  Regeneron: Need fair drug prices CNBC
Feb-18-15 04:04PM  Buffetts Berkshire Hathaway Sells Exxon, ConocoPhilips, Buys Deere, IBM at TheStreet
06:34AM  Chairs: CVS' red flag on costly drugs CNBC
Feb-17-15 05:55PM  CVS urges cost controls for new cholesterol drugs Reuters
12:26PM  AmerisourceBergen Corporation -- Moody's assigns Baa2 to AmerisourceBergen's new sr unsecured notes; outlook stable at Moody's
Feb-12-15 01:30PM  AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog Zacks
11:40AM  Rite Aid (RAD) Jumps 6.6% on TPG's EnvisionRx Buyout - Analyst Blog Zacks
Feb-11-15 05:50PM  Rite Aid Stock Soars, Steps Up Competition With CVS at Investor's Business Daily
02:53PM  AstraZeneca to pay $7.9 million over kickback allegations AP
11:07AM  Rite Aid: The Next CVS? at Barrons.com
10:03AM  Hey Abbvie, Don't Start What You Can't Finish Yahoo Finance Contributors
09:04AM  Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price at TheStreet
08:45AM  Rite Aid to pay $2B for EnvisionRx at USA TODAY
08:10AM  Rite Aid to pay $2B for pharmacy benefits manager EnvisionRx AP
Feb-06-15 05:47PM  Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog Zacks
05:21PM  Drug price wars 'drive value': Medical exec at CNBC
03:19PM  Drug price battles CNBC
Feb-04-15 12:13PM  Pricing wars heat up over hepatitis C drugs at CNBC
Feb-03-15 07:43PM  Gilead to cut price of $1,000-a-day pill at Financial Times
07:26PM  Gilead Profit Soars But HCV Drug Rival Weighs On Outlook Investor's Business Daily
06:41PM  Gilead boosts hepatitis C drug discounts, shares slide Reuters
Feb-02-15 03:30PM  Will Gilead (GILD) Miss Q4 Earnings on Low HCV Drug Sales? - Analyst Blog Zacks
Jan-30-15 01:24PM  AbbVie expects hep C drug sales to top $3 billion per year Reuters
12:07PM  AbbVie reports better-than-expected 4Q on Humira sales AP
10:10AM  Abbvie Expects $3B In Hepatitis C Drug Sales And 40% Of Insured Customers at Forbes
08:20AM  Competition in Hepatitis C drug market lowering cost of expensive treatment at American City Business Journals
Jan-29-15 02:18PM  Baird Remains Buyers Of Gilead Before Earnings Release Benzinga
Jan-28-15 06:00PM  Cramer: Market struggles to find footing CNBC
06:29AM  Express Scripts downgraded by FBR Capital Briefing.com
Jan-26-15 12:00AM  Want To Control Drug Prices? Reject Price Controls at Forbes
Jan-24-15 11:58AM  German insurers win discounts on Gilead's Sovaldi Reuters
Jan-22-15 07:49PM  The Drug Price War Pitting Insurers Against Big Pharma at Bloomberg
02:42PM  Express Scripts Targets $150,000 Cancer Drug Prices in 2016 Plan at Bloomberg
Jan-21-15 02:13PM  Gilead, AbbVie Hep C Price Cuts Seen Hitting Sales at Investor's Business Daily
Jan-20-15 10:00AM  Benefits firms shouldn't play drug favorites: CEO at CNBC
07:41AM  Regeneron CEO: Choice, not price best for patients CNBC
Jan-19-15 06:35PM  AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst Blog Zacks
Jan-18-15 10:32AM  5 Trade Ideas for Tuesday: Allstate, Anheuser-Busch InBev, Ashland, Express Scripts, Northrup Grumman, Yahoo Finance Contributors
Jan-16-15 05:34PM  Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's AP
05:19PM  CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead's hepatitis C treatment, gets discount Reuters
04:15PM  Express Scripts Announces Fourth Quarter 2014 Earnings Conference Call and Webcast of Investor Day Meeting PR Newswire
03:43PM  Aetna Sides With Gilead In Hepatitis C Drug Battle at Investor's Business Daily
03:08PM  Gilead Strikes Another Deal at Barrons.com
07:00AM  Express Scripts Holding Company (ESRX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-15-15 10:59AM  5 Breakout Trades for 2015 Gains: Apple, Goldman Sachs and More at TheStreet
01:00AM  Big Pharma faces up to new price pressure from aggressive insurers Reuters
Jan-14-15 04:02PM  Express Scripts facing antitrust, contract complaint at American City Business Journals
09:01AM  Cramer: Market in weird place CNBC
Jan-13-15 07:10PM  Steven Romick Buys 7 US and International Stocks in Q4 Gurufocus
06:14PM  Cramer's guide to a treacherous trader's market at CNBC
04:28PM  Express Scripts sees opportunity to lower cancer treatment cost Reuters
03:38PM  Express Scripts sees opportunity to lower cancer treatment costs Reuters
02:41PM  Will Earnings or the European Central Bank Prompt U.S. Stocks to Rise? at TheStreet
01:35PM  State of St. Louis: Stenger focuses on Childrens Service Fund at American City Business Journals
12:46PM  Express Scripts CEO: Amgen, Regeneron Among Targets for Drug Discounting at TheStreet
Jan-12-15 12:57PM  AmerisourceBergen Corporation -- Moody's affirms AmerisourceBergen's Baa2 rating on news of MWI Veterinary acquisition at Moody's
11:03AM  Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2 Benzinga
Jan-09-15 11:49AM  AbbVie Stock Down After Guidance, Downgrade at Investor's Business Daily
09:55AM  Gilead Sciences: Winning at Barrons.com
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. The company's PBM segment's services include clinical solutions to enhance health outcomes, such as adherence, case coordination, and personalized medicine; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services for pharmaceutical manufacturers to collect scientific evidence to guide the use of medicines, as well as case management approach to manage care by integrating pre-certification, case management, and discharge planning services for patients. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists, and others. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Mar 02Sale84.392,674225,6598,291Mar 03 04:15 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Feb 25Sale87.315,864511,98610,965Feb 26 04:03 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Feb 24Option Exercise47.6121,7391,034,99438,568Feb 26 04:03 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Feb 24Sale87.6221,7391,904,77016,829Feb 26 04:03 PM
Ebling Keith J.Exec. VP and General CounselDec 02Sale84.2510,000842,5000Dec 03 04:04 PM
Miller Steven BSr. VP & Chief Med. OfficerDec 01Sale83.574,896409,14416,521Dec 03 04:07 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 28Option Exercise47.6110,800514,18830,657Dec 01 04:03 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 28Sale82.9610,800895,94619,857Dec 01 04:03 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 21Option Exercise47.6110,874517,71130,731Nov 25 04:38 PM
MAC MAHON THOMAS PDirectorNov 21Option Exercise35.8512,694455,01654,066Nov 25 04:40 PM
MAC MAHON THOMAS PDirectorNov 21Sale80.9312,6941,027,35141,372Nov 25 04:40 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Nov 21Sale81.5010,874886,23119,857Nov 25 04:38 PM
PARKER JOHN ODirectorNov 17Option Exercise33.3025,822859,75365,503Nov 18 05:04 PM
PARKER JOHN ODirectorNov 17Sale78.7525,8222,033,43139,681Nov 18 05:04 PM
Breen Maura CDirectorNov 07Option Exercise30.8313,128404,73630,438Nov 10 04:16 PM
Breen Maura CDirectorNov 07Sale77.8013,1281,021,34517,310Nov 10 04:16 PM
IGNACZAK EDWARD BEVPSep 05Sale75.289,886744,21675,996Sep 09 05:01 PM
STERNBERG SEYMOURDirectorAug 28Option Exercise54.3015,508842,07920,277Sep 02 04:07 PM
STERNBERG SEYMOURDirectorAug 28Sale74.1215,5081,149,3914,769Sep 02 04:07 PM
Ebling Keith J.Exec. VP and General CounselAug 25Sale75.5010,000755,00010,000Aug 26 04:04 PM
Wade Sara ESr. VP, Ch. Human Res. Off.Aug 05Option Exercise53.0520,0001,061,00049,532Aug 06 04:10 PM
BENANAV GARY GDirectorAug 05Option Exercise35.8512,694455,01655,705Aug 07 04:08 PM
BENANAV GARY GDirectorAug 05Sale70.8212,694898,98943,011Aug 07 04:08 PM
Wade Sara ESr. VP, Ch. Human Res. Off.Aug 05Sale70.4420,0001,408,80029,532Aug 06 04:10 PM
Norton David ASenior VP, Supply ChainAug 04Sale71.021,27690,6270Aug 06 04:13 PM
Breen Maura CDirectorAug 01Option Exercise35.8512,694455,01630,283Aug 05 04:55 PM
Breen Maura CDirectorAug 01Sale69.9412,694887,75517,589Aug 05 04:55 PM
PAZ GEORGEChairman & CEOJun 13Option Exercise26.68681,50818,179,3841,469,761Jun 17 05:04 PM
PAZ GEORGEChairman & CEOJun 13Sale71.21681,50848,530,185788,253Jun 17 05:04 PM
WENTWORTH TIMOTHY CPresidentMay 27Option Exercise47.25127,1896,009,516228,492May 29 05:03 PM
WENTWORTH TIMOTHY CPresidentMay 27Sale70.47105,6777,447,058122,815May 29 05:03 PM
Wimberly GarySr. VP & Ch. Information Off.Mar 13Option Exercise45.3934,5361,567,69758,157Mar 17 04:34 PM
Wimberly GarySr. VP & Ch. Information Off.Mar 13Sale78.4144,4973,489,09913,660Mar 17 04:34 PM
Houston ChristineSr. Vice President, OperationsMar 12Option Exercise31.9215,674500,31438,071Mar 14 06:24 PM
Houston ChristineSr. Vice President, OperationsMar 12Sale78.5319,7571,551,45818,314Mar 14 06:24 PM
IGNACZAK EDWARD BExec. VP, Sales and MktgMar 11Option Exercise55.14120,2476,630,559206,129Mar 13 05:42 PM
IGNACZAK EDWARD BExec. VP, Sales and MktgMar 11Sale78.54120,2479,443,83985,882Mar 13 05:42 PM
Norton David ASenior VP, Supply ChainMar 11Sale79.153,160250,123630Mar 13 05:38 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 11Sale79.009,582756,97820,000Mar 11 06:02 PM
Miller Steven BSr. VP & Chief Med. OfficerMar 10Sale77.9612,664987,29821,417Mar 12 06:05 PM
McNamee PatrickExec. VP and COOMar 10Sale78.2227,9812,188,5627,664Mar 12 06:03 PM
McNamee PatrickExec. VP and COOMar 10Sale78.3240,4443,167,69512,421Mar 12 06:03 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 07Option Exercise49.509,901490,05038,361Mar 11 06:02 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Mar 07Option Exercise47.1437,4311,764,58363,624Mar 11 06:04 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 07Sale77.6737,6612,925,17829,582Mar 07 06:44 PM
Stettin Glen D.Sr. VP, Clin. Res. & New Sol.Mar 07Sale78.2243,7673,423,23919,857Mar 11 06:04 PM
Ebling Keith J.Exec. VP and Gen. CounselMar 07Sale78.5016,1391,266,92822,222Mar 11 06:02 PM